PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7951541

Plasma polymorphonuclear elastase in patients with hyperthyroidism.

H Hara·Y Ban
View original source ↗Export metadata ↓

Abstract

We studied plasma polymorphonuclear elastase (PMNE) levels before and during methimazole treatment in patients with hyperthyroidism. Plasma PMNE levels in patients with hyperthyroidism were significantly higher than those of normal subjects and patients with thyroid adenoma. Plasma PMNE levels in patients with Graves' disease were significantly reduced when their thyroid functions after methimazole treatment were normal, compared with the levels of the patients before treatment. In patients with hyperthyroidism there was a significant positive correlation between plasma PMNE and serum FT3, but no correlation between plasma PMNE and serum TRAb. The results suggested that PMNE was secreted from blood neutrophil in hyperthyroid state patients with Graves' disease and that it was beneficial for helping determining peripheral thyroid function.

Explore related subjects

AdenomaAdultFemaleGraves DiseaseHumansImmunoglobulins, Thyroid-StimulatingMaleMiddle AgedNeoplasm ProteinsNeutrophilsPancreatic ElastaseThyroid HormonesThyroid NeoplasmsThyroiditis, SubacuteThyrotropinJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H Hara, Y Ban. 1993. Plasma polymorphonuclear elastase in patients with hyperthyroidism.. https://doi.org/10.1507/endocrj.40.711

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2009

HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas.

The high mobility group As (HMGAs) belong to a family of nonhistone nuclear proteins that orchestrate the assembly of nucleoprotein complexes. Through a complex network of protein-DNA and protein-protein interaction, they play important roles in gene transcription, recombination, and chromatin structure. This protein family is involved, through different mechanisms, in both benign and malignant neoplasias. We have recently reported that transgenic mice carrying the Hmga1 or Hmga2 genes under transcriptional control of the cytomegalovirus promoter develop pituitary adenomas secreting prolactin and growth hormone. We have shown that the mechanism of the HMGA2-induced pituitary adenoma is based on the increased E2F1 activity. The expression profile of mouse normal pituitary glands and adenomas induced in HMGA transgenic mice revealed an increased expression of the ccnb2 gene, coding for the cyclin B2 protein, in the neoplastic tissues compared with the normal pituitary gland. Here, we show, by electrophoretic mobility shift assay and chromatin immunoprecipitation, a direct binding of HMGA proteins to the promoter of ccnb2 gene, whereas luciferase assays showed that HMGAs are able to up-regulate ccnb2 promoter activity. Finally, we report an increased CCNB2 expression in human pituitary adenomas of different histotypes that is directly correlated with HMGA1 and HMGA2 expression. Because cyclin B2 is involved in the regulation of the cell cycle, these results taken together indicate that HMGA-induced cyclin B2 overexpression gives an important contribution to experimental and human pituitary tumorigenesis.

Adenoma↗
PubMed1997

Mutations of the MEN1 tumor suppressor gene in pituitary tumors.

Although pituitary adenomas are monoclonal proliferations, somatic mutations involving genes that govern cell proliferation or hormone production have been difficult to identify. The genetic etiology of most pituitary tumors, therefore, remains unknown. Pituitary adenomas can develop sporadically or as a part of multiple endocrine neoplasia type 1 (MEN1). Recently, the gene responsible for MEN1 was cloned. To elucidate the potential etiological role of the MEN1 gene in pituitary tumorigenesis, 39 sporadic pituitary adenomas from 38 patients and 1 pituitary adenoma from a familial MEN1 patient were examined for MEN1 gene mutations and allelic deletions. Four of 39 sporadic pituitary adenomas showed a deletion of one copy of the MEN1 gene, and a specific MEN1 gene mutation in the remaining gene copy was detected in 2 of these tumors. The corresponding germ-line sequence was normal in all sporadic cases. A specific MEN1 mutation was detected in a pituitary adenoma and corresponding germ-line DNA in a patient with familial MEN1. An allelic deletion of the remaining copy of the MEN1 gene was also found in the patient's tumor. Genetic alterations of the MEN1 gene represent a candidate pathogenetic mechanism of pituitary tumorigenesis. The data suggest that somatic MEN1 gene mutations and deletions play a causative role in the development of a subgroup of sporadic pituitary adenomas.

Adenoma↗